EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitSystematische ÜbersichtMetaanalyseOpen Access · CC BY 4.0

Safety of Single High-Dose Liposomal Amphotericin B for Induction Treatment of Cryptococcal Meningitis and Histoplasmosis in People With HIV: A Systematic Review and Meta-analysis

HeeEun Kang iD, John P Uy, Caroline C Ho, Heather B Blunt, Natalie B Riblet, Alessandro C Pasqualotto, Richard A Murphy

Open Forum Infectious Diseases · 30.09.2023 · 10 (10)

DOI: 10.1093/ofid/ofad472 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Open Forum Infectious Diseases, online erschienen am 20.09.2023. Verfasst von HeeEun Kang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Infectious Disease and International Health, Department of Medicine, Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, USA. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Evidence for efficacy of single, high-dose liposomal amphotericin B (LAmB) in HIV-associated cryptococcal meningitis and histoplasmosis is growing. No systematic review has examined the safety of this regimen across multiple studies.

Methods

We systematically searched Medline, Scopus, and the Cochrane Library from inception to April 2023 for studies reporting grade 3 and 4 adverse events (AEs) with single high-dose LAmB vs traditional amphotericin regimens for HIV-associated fungal infections.

Results

Three trials (n = 946) were included. Compared with traditional regimens, single high-dose LAmB was associated with equivalent risk of grade 3 and 4 AEs (risk ratio [RR], 0.75; 95% CI, 0.53–1.06) and lower overall risk of grade 4 AEs (RR, 0.68; 95% CI, 0.55–0.86), grade 4 renal (RR, 0.43; 95% CI, 0.20–0.94) and grade 4 hematological AEs (RR, 0.46; 95% CI, 0.32–0.65).

Conclusions

Single, high-dose LAmB is associated with a lower risk of life-threatening AEs compared with other World Health Organization–endorsed amphotericin B–based regimens in invasive HIV–related fungal infection.

Schlagwörter

Stichwörter der Autor:innen

HIV infectionantifungalcryptococcal meningitishistoplasmosisopportunistic infections

Autor:innen und Institutionen

  • Infectious Disease and International Health, Department of Medicine, Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, USA.
  • Geisel School of Medicine at Dartmouth, Hanover, New Hampshire, USA.
  • Infectious Diseases, Universidade Federal de Ciências da Saúde de Porto Alegre, Porto Alegre, Brazil.
  • White River Junction VA Medical Center, Hartford, Vermont, USA.

ORCID-Profile: HeeEun Kang

Zitieren

APA

Kang, H., Uy, J. P., Ho, C. C., Blunt, H. B., Riblet, N. B., Pasqualotto, A. C., & Murphy, R. A. (2023). Safety of Single High-Dose Liposomal Amphotericin B for Induction Treatment of Cryptococcal Meningitis and Histoplasmosis in People With HIV: A Systematic Review and Meta-analysis. Open Forum Infectious Diseases, 10(10). https://doi.org/10.1093/ofid/ofad472

Vancouver

Kang H, Uy JP, Ho CC, Blunt HB, Riblet NB, Pasqualotto AC, et al. Safety of Single High-Dose Liposomal Amphotericin B for Induction Treatment of Cryptococcal Meningitis and Histoplasmosis in People With HIV: A Systematic Review and Meta-analysis. Open Forum Infectious Diseases. 2023;10(10). doi:10.1093/ofid/ofad472

BibTeX
@article{Kang2023,
  author = {Kang, HeeEun and Uy, John P and Ho, Caroline C and Blunt, Heather B and Riblet, Natalie B and Pasqualotto, Alessandro C and Murphy, Richard A},
  title = {Safety of Single High-Dose Liposomal Amphotericin B for Induction Treatment of Cryptococcal Meningitis and Histoplasmosis in People With HIV: A Systematic Review and Meta-analysis},
  journal = {Open Forum Infectious Diseases},
  year = {2023},
  volume = {10},
  number = {10},
  doi = {10.1093/ofid/ofad472}
}
Kostenlos starten →